CN1636564A - 含烷氧基取代苯并咪唑化合物的组合物和药物制剂及其制法 - Google Patents

含烷氧基取代苯并咪唑化合物的组合物和药物制剂及其制法 Download PDF

Info

Publication number
CN1636564A
CN1636564A CNA2004100946486A CN200410094648A CN1636564A CN 1636564 A CN1636564 A CN 1636564A CN A2004100946486 A CNA2004100946486 A CN A2004100946486A CN 200410094648 A CN200410094648 A CN 200410094648A CN 1636564 A CN1636564 A CN 1636564A
Authority
CN
China
Prior art keywords
methoxyl group
methyl
benzimidazole
dimethyl
sulfinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004100946486A
Other languages
English (en)
Chinese (zh)
Inventor
R·R·怀特勒
F·D·桑茨利奥
G·W·斯托维尔
D·J·詹金斯
L·怀塔尔
G·A·梅耶
S·A·丰塔纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AAIPharma Inc
Original Assignee
Applied Analytical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/519,976 external-priority patent/US6262085B1/en
Application filed by Applied Analytical Industries Inc filed Critical Applied Analytical Industries Inc
Publication of CN1636564A publication Critical patent/CN1636564A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004100946486A 1999-08-26 2000-08-25 含烷氧基取代苯并咪唑化合物的组合物和药物制剂及其制法 Pending CN1636564A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15087899P 1999-08-26 1999-08-26
US60/150878 1999-08-26
US09/519976 2000-03-07
US09/519,976 US6262085B1 (en) 1999-08-26 2000-03-07 Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB008149232A Division CN1183127C (zh) 1999-08-26 2000-08-25 烷氧基取代的苯并咪唑化合物,含有它们的药物制剂及使用它们的方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2006101016924A Division CN1880312A (zh) 1999-08-26 2000-08-25 烷氧基取代苯并咪唑化合物和含它们的组合物及药物制剂

Publications (1)

Publication Number Publication Date
CN1636564A true CN1636564A (zh) 2005-07-13

Family

ID=26848119

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2004100946486A Pending CN1636564A (zh) 1999-08-26 2000-08-25 含烷氧基取代苯并咪唑化合物的组合物和药物制剂及其制法
CNB008149232A Expired - Fee Related CN1183127C (zh) 1999-08-26 2000-08-25 烷氧基取代的苯并咪唑化合物,含有它们的药物制剂及使用它们的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB008149232A Expired - Fee Related CN1183127C (zh) 1999-08-26 2000-08-25 烷氧基取代的苯并咪唑化合物,含有它们的药物制剂及使用它们的方法

Country Status (16)

Country Link
EP (1) EP1206466B1 (enExample)
JP (1) JP4312405B2 (enExample)
KR (1) KR100712039B1 (enExample)
CN (2) CN1636564A (enExample)
AT (1) ATE306483T1 (enExample)
AU (2) AU777667B2 (enExample)
BR (1) BR0014145A (enExample)
CA (1) CA2382867A1 (enExample)
DE (1) DE60023154T2 (enExample)
HR (1) HRP20020174A2 (enExample)
MX (1) MXPA02002007A (enExample)
NO (1) NO326849B1 (enExample)
RO (1) RO122491B1 (enExample)
RU (1) RU2263673C2 (enExample)
SI (1) SI20974A (enExample)
SK (1) SK286903B6 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114558004A (zh) * 2022-03-29 2022-05-31 奎马特里克斯有限公司 Qtx125药物制剂
CN115190835A (zh) * 2020-03-09 2022-10-14 艾德克斯实验室公司 在将液体样品分配在化学试剂试验载玻片上之前从液体样品中除去干扰组分的方法
CN116082247A (zh) * 2023-01-19 2023-05-09 浙江工业大学 一种苯并咪唑类衍生物及其应用
CN118225938A (zh) * 2024-04-02 2024-06-21 江苏海洋大学 一种中药复方五神汤的质量检测方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
WO2006001753A1 (en) 2004-06-24 2006-01-05 Astrazeneca Ab New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
CN103524491A (zh) * 2013-10-16 2014-01-22 江南大学 埃索美拉唑镁盐四水合物的三种晶型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US895292A (en) * 1904-07-22 1908-08-04 Marvin A Neeland Blowing-engine inlet-valve.
SE418966B (sv) * 1974-02-18 1981-07-06 Haessle Ab Analogiforfarande for framstellning av foreningar med magsyrasekretionsinhiberande verkan
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115190835A (zh) * 2020-03-09 2022-10-14 艾德克斯实验室公司 在将液体样品分配在化学试剂试验载玻片上之前从液体样品中除去干扰组分的方法
CN114558004A (zh) * 2022-03-29 2022-05-31 奎马特里克斯有限公司 Qtx125药物制剂
CN114558004B (zh) * 2022-03-29 2023-08-11 奎马特里克斯有限公司 Qtx125药物制剂
CN116082247A (zh) * 2023-01-19 2023-05-09 浙江工业大学 一种苯并咪唑类衍生物及其应用
CN118225938A (zh) * 2024-04-02 2024-06-21 江苏海洋大学 一种中药复方五神汤的质量检测方法

Also Published As

Publication number Publication date
CN1384831A (zh) 2002-12-11
AU777667B2 (en) 2004-10-28
CA2382867A1 (en) 2001-03-01
DE60023154D1 (de) 2006-02-23
AU2005200203B2 (en) 2008-01-10
JP2003507475A (ja) 2003-02-25
CN1183127C (zh) 2005-01-05
SI20974A (sl) 2003-02-28
JP4312405B2 (ja) 2009-08-12
KR20020035861A (ko) 2002-05-15
RO122491B1 (ro) 2009-07-30
KR100712039B1 (ko) 2007-04-27
EP1206466A1 (en) 2002-05-22
AU7073700A (en) 2001-03-19
NO326849B1 (no) 2009-03-02
SK286903B6 (sk) 2009-07-06
SK2812002A3 (en) 2002-07-02
HRP20020174A2 (en) 2005-12-31
EP1206466B1 (en) 2005-10-12
MXPA02002007A (es) 2003-08-20
BR0014145A (pt) 2002-05-14
RU2263673C2 (ru) 2005-11-10
DE60023154T2 (de) 2006-06-22
NO20020914D0 (no) 2002-02-25
ATE306483T1 (de) 2005-10-15
NO20020914L (no) 2002-04-26
AU2005200203A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
CN1254473C (zh) (r)－或(s)－兰索拉唑的结晶方法
CN1182841C (zh) 新的药物制剂及其制备方法
CN1152671C (zh) 含有质子泵抑制剂的多单元药物制剂
CN1171587C (zh) 含有γ-氨基丁酸衍生物的固体组合物及其制备方法
CN100335043C (zh) 片剂化多重单元泡腾剂剂型口服药物组合物及其生产方法
US6667323B1 (en) Dry-blend pharmaceutical formulations
CN1171885C (zh) 苯并咪唑衍生物晶体及其制备
CN1098104C (zh) 新的口服药用剂型
CN1076124A (zh) 一种用于制备含有酸不稳定化合物的肠溶衣口服药的方法
US6268385B1 (en) Dry blend pharmaceutical formulations
CN1571659A (zh) 含大量酸不稳定药物的颗粒
CN1890220A (zh) 4－(3－氯－4－(环丙基氨基羰基)氨基苯氧基)－7－甲氧基－6－喹啉羧酰胺的盐或其溶剂合物的结晶及其制备方法
CN1678589A (zh) 作为药物的新氨基吲唑衍生物与含有它们的药物组合物
CN1523979A (zh) 非晶形药物吸附物的药物组合物
CN87103284A (zh) 用作口服的新的药用制剂
US6262086B1 (en) Pharmaceutical unit dosage form
CN1183127C (zh) 烷氧基取代的苯并咪唑化合物,含有它们的药物制剂及使用它们的方法
US6326384B1 (en) Dry blend pharmaceutical unit dosage form
CN1880312A (zh) 烷氧基取代苯并咪唑化合物和含它们的组合物及药物制剂
CN101048180A (zh) 具有改善的溶解度和稳定性的固体制剂和用于制备所述制剂的方法
CN1487936A (zh) 具有改进吸收性能的药物组合物
CN1678315A (zh) 用于治疗如消化性溃疡的质子泵抑制剂咪唑衍生物的前药
CN1407984A (zh) 新的1,8－二氮杂萘－2(1h)－酮衍生物
CN1214632A (zh) 艾滋病治疗剂或预防剂
HK1047277A1 (zh) 吡嗪酮凝血酶抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050713